A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis.
Verstovsek, S
A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis. [electronic resource] - Leukemia 02 2017 - 393-402 p. digital
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
1476-5551
10.1038/leu.2016.215 doi
Adult
Aged
Aged, 80 and over
Alleles
Antineoplastic Agents--pharmacology
Biomarkers
Bone Marrow--pathology
Female
Follow-Up Studies
Humans
Janus Kinase 2--antagonists & inhibitors
Male
Middle Aged
Molecular Targeted Therapy
Neoplasm Grading
Phenotype
Primary Myelofibrosis--diagnosis
Protein Kinase Inhibitors--pharmacology
Retreatment
Treatment Outcome
A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis. [electronic resource] - Leukemia 02 2017 - 393-402 p. digital
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
1476-5551
10.1038/leu.2016.215 doi
Adult
Aged
Aged, 80 and over
Alleles
Antineoplastic Agents--pharmacology
Biomarkers
Bone Marrow--pathology
Female
Follow-Up Studies
Humans
Janus Kinase 2--antagonists & inhibitors
Male
Middle Aged
Molecular Targeted Therapy
Neoplasm Grading
Phenotype
Primary Myelofibrosis--diagnosis
Protein Kinase Inhibitors--pharmacology
Retreatment
Treatment Outcome